ZYVERSA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Increase (Decrease) in Accrued Liabilities of $1.42 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2022-11-14
- ZYVERSA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $849.68K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month |
|---|---|---|---|
| 2022-09-30 | $849.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.42M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $575.22K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |